Comparative Pharmacology
Head-to-head clinical analysis: VANCOMYCIN HYDROCHLORIDE versus VANCOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VANCOMYCIN HYDROCHLORIDE versus VANCOR.
VANCOMYCIN HYDROCHLORIDE vs VANCOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Vancomycin inhibits bacterial cell wall synthesis by binding to the D-alanyl-D-alanine terminus of the pentapeptide precursor, preventing transpeptidation and polymerization of peptidoglycan.
Inhibits cell wall synthesis by binding to the D-alanyl-D-alanine terminus of peptidoglycan precursors, blocking transglycosylation and transpeptidation.
1-2 g IV every 12 hours; adjust based on trough concentrations (target 10-20 mcg/mL).
Vancomycin 15-20 mg/kg IV every 8-12 hours, with target trough 10-20 mcg/mL; for serious infections, consider loading dose 25-30 mg/kg IV.
None Documented
None Documented
4-6 hours in adults with normal renal function; prolonged up to 7 days in anuria. Half-life inversely correlates with creatinine clearance.
Terminal elimination half-life is 4-6 hours in adults with normal renal function; can extend to 7-9 days in anuric patients, necessitating therapeutic drug monitoring.
Renal: 80-90% unchanged via glomerular filtration; minor biliary (up to 5%) and fecal elimination.
Renal excretion of unchanged drug accounts for 80-90% of clearance via glomerular filtration; minor biliary excretion (<5%) and fecal elimination (<5%).
Category A/B
Category C
Glycopeptide Antibiotic
Glycopeptide Antibiotic